Co-Authors
This is a "connection" page, showing publications co-authored by AMY B HEIMBERGER and JASON HUSE.
Connection Strength
1.792
-
A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol. 2022 06 01; 11(2):CNS87.
Score: 0.216
-
CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease. Front Immunol. 2021; 12:745893.
Score: 0.207
-
Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI Insight. 2020 09 03; 5(17).
Score: 0.192
-
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577.
Score: 0.187
-
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
Score: 0.187
-
Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2019 01 02; 129(1):137-149.
Score: 0.169
-
Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. J Neuropathol Exp Neurol. 2018 06 01; 77(6):437-442.
Score: 0.164
-
Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology. 2018; 7(4):e1412909.
Score: 0.160
-
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017 Aug 01; 19(8):1047-1057.
Score: 0.155
-
Response of treatment-naive brain metastases to stereotactic radiosurgery. Nat Commun. 2024 May 02; 15(1):3728.
Score: 0.062
-
Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression. JCI Insight. 2022 05 09; 7(9).
Score: 0.054
-
Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design. J Neurooncol. 2018 Sep; 139(2):469-478.
Score: 0.041